Healthy cells in our body release nano-sized bubbles that transfer genetic material such as DNA and RNA to other cells. It’s your DNA that stores the important information necessary for RNA to produce proteins and make sure they act accordingly.
These bubbly extracellular vesicles could become mini treatment transporters, carrying a combination of therapeutic drugs and genes that target cancer cells and kill them, according to new research from Michigan State University and Stanford University.
The study, which focused on breast cancer cells in mice, is published in Molecular Cancer Therapeutics.
“What we’ve done is improve a therapeutic approach to delivering enzyme-producing genes that can convert certain drugs into toxic agents and target tumors,” said Masamitsu Kanada, lead author and an assistant professor of pharmacology and toxicology in MSU’s Institute for Quantitative Health Science and Engineering.
These drugs, or prodrugs, start out as inactive compounds. But once they metabolize in the body, they’re immediately activated and can get to work on fighting everything from cancer to headaches. Aspirin is an example of a common prodrug.
In this case, researchers used extracellular vesicles, or EVs, to deliver the enzyme-producing genes that could activate a prodrug combination therapy of ganciclovir and CB1954 in breast cancer cells. Minicircle DNA and regular plasmid – two different gene vectors that act as additional delivery mechanisms for DNA – were loaded into the vesicles to see which was better at helping transport treatment. This is known as a gene-directed enzyme, prodrug therapy.
They found that the minicircle DNA was 14 times more effective at delivery and even more successful at killing cancerous tumors.
“Interestingly, the plasmid delivery method didn’t show any tumor cell killing,” Kanada said. “Yet the minicircle DNA-based therapy killed more than half of the breast cancer cells in the mice.”
According to Kanada, this new approach could effectively become a better cancer treatment option than chemotherapy down the road.
“Conventional chemotherapy isn’t able to differentiate between tumors and normal tissue, so it attacks it all,” Kanada said. “This non-specificity can cause severe side effects and insufficient drug concentration in tumors.”
With EVs, treatment can be targeted and because of their compatibility with the human body, this type of delivery could minimize the risk of unwanted immune responses that can come with other gene therapies.
“If EVs prove to be effective in humans, it would be an ideal platform for gene delivery and it could be used in humans sooner than we expect,” Kanada said.
A phase-one clinical trial, separate from Kanada’s work, is set to start soon in the U.S. and will use EVs and a type of therapeutic RNA molecule for the treatment of metastatic pancreatic cancer.
While that trial moves forward, Kanada and his team will continue to further engineer and test EVs, improving their effectiveness and safety so using them as a cancer-fighting gene therapy in humans becomes reality.
The study was funded in part by the National Institutes of Health.
(Note for media: Please include a link to the original paper in online coverage: https://mct.aacrjournals.org/content/early/2019/08/28/1535-7163.MCT-19-0299.long)